Urogen Pharma (NASDAQ:URGN) Insider Mark Schoenberg Sells 871 Shares

Urogen Pharma (NASDAQ:URGN) insider Mark Schoenberg sold 871 shares of the stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $42.92, for a total transaction of $37,383.32. Following the completion of the sale, the insider owned 59,882 shares in the company, valued at $2,570,135.44. The trade was a 1.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Mark Schoenberg also recently made the following trade(s):

• On Thursday, August 20th, Mark Schoenberg sold 60,677 shares of Urogen Pharma stock. The shares were sold at an average price of $47.05, for a total transaction of $2,854,852.85.
• On Thursday, July 9th, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The shares were sold at an average price of $40.00, for a total transaction of $400,000.00.
• On Monday, June 22nd, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The stock was sold at an average price of $35.01, for a total value of $350,100.00.

Urogen Pharma Stock Up 2.7%

Shares of URGN stock opened at $45.00 on Thursday. Urogen Pharma has a 52-week low of $15.86 and a 52-week high of $50.81. The stock has a market cap of $2.20 billion, a PE ratio of -22.73 and a beta of 1.57. The business has a 50-day simple moving average of $43.16 and a 200-day simple moving average of $31.31.

Urogen Pharma (NASDAQ:URGN) last posted its earnings results on Wednesday, August 5th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The company had revenue of $72.46 million during the quarter, compared to analysts’ expectations of $63.55 million. Sell-side analysts anticipate that Urogen Pharma will post -0.2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

URGN has been the subject of several recent research reports. TD Cowen lifted their target price on shares of Urogen Pharma from $50.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a report on Friday, July 17th. The Goldman Sachs Group restated a “neutral” rating and set a $44.00 price target on shares of Urogen Pharma in a research report on Wednesday, July 15th. Oppenheimer lifted their price objective on shares of Urogen Pharma from $40.00 to $50.00 and gave the company an “outperform” rating in a report on Thursday, July 16th. Finally, HC Wainwright increased their target price on shares of Urogen Pharma from $45.00 to $75.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Urogen Pharma has an average rating of “Moderate Buy” and a consensus target price of $52.38.

Institutional Investors Weigh In On Urogen Pharma

Institutional investors have recently added to or reduced their stakes in the stock. Persistent Asset Partners Ltd purchased a new stake in Urogen Pharma in the 2nd quarter worth $66,000. Quantbot Technologies LP purchased a new stake in shares of Urogen Pharma during the second quarter worth about $78,000. Russell Investments Group Ltd. increased its stake in shares of Urogen Pharma by 1,594.4% during the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock worth $66,000 after purchasing an additional 3,125 shares in the last quarter. Osaic Holdings Inc. raised its position in shares of Urogen Pharma by 491.2% during the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after purchasing an additional 3,070 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in Urogen Pharma by 422.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock valued at $94,000 after buying an additional 5,571 shares in the last quarter. Institutional investors and hedge funds own 91.29% of the company’s stock.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.